<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568672</url>
  </required_header>
  <id_info>
    <org_study_id>2007-000512-82</org_study_id>
    <secondary_id>Franziska Jakob, MD</secondary_id>
    <secondary_id>Ion Anghelescu, MD</secondary_id>
    <nct_id>NCT00568672</nct_id>
  </id_info>
  <brief_title>Optimal Duration of Olanzapine Add-on Therapy in Major Depression</brief_title>
  <acronym>OLA-D</acronym>
  <official_title>Optimal Duration of Olanzapine Add-on Therapy in Major Depression: a Placebo-Controlled, Randomized, Phase III, Pilot Study in Parallel Group Design</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of olanzapine versus placebo in the continuation therapy of subjects with major
      depression who had a response with additional olanzapine to an antidepressant.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Withdrawn because of personal ressources before inclusion of the first patient
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">April 2008</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relapse Rate, Hamilton Depression Rating Scale (17 item version)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and side effect scales (SWN Scale, CGI), Beck Depression Inventory</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Relapse Rate of a Major Depressive Episode</condition>
  <condition>Safety of Olanzapine in Subjects With Major Depression</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Olanzapine 5 mg / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Olanzapine 5 mg / day for 6 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>EU/1/96/022/002+019</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed consent

          -  age 18 - 80

          -  diagnosis of major depression according dsm-iv, unipolar course

          -  Hamilton-Depression-Rating-Scale (17 item score) &gt; 18 prior to inclusion

          -  response towards therapy with antidepressant and olanzapine as defined &gt; 50 %
             reduction of HAMDD score

          -  negative pregancy test

          -  highly effective contraceptive method in women

          -  no participation in other trial according to German Drug Laq

          -  normal liver function

        Exclusion Criteria:

          -  pregnancy, lactation

          -  depressive episode secondary to somatic disease or substance dependency

          -  contraindication for olanzapine

          -  treatment with interacting substances (CYP1A2 inhibitors or inductors)

          -  comorbidity according to DSM-IV, axis I

          -  denail of consent

          -  hospital treatment by legal order

          -  hepatic insufficiency

          -  severe neurological or medical disease

          -  adipositas permagna

          -  HIV-infection

          -  active viral hapatitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ion Anghelescu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charité - University Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arnim Quante, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite, University Berlin, Campus Benjamin Franklin, Department of Psychiatry and Psychotherapy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departement of Psychiatry and Psychotherapy, Charite, University Medicine Berlin, Campus Benjamin Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>14050</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2007</study_first_submitted>
  <study_first_submitted_qc>December 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2007</study_first_posted>
  <last_update_submitted>April 23, 2008</last_update_submitted>
  <last_update_submitted_qc>April 23, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Ion Anghelescu, MD</name_title>
    <organization>Charité University Berlin</organization>
  </responsible_party>
  <keyword>Major Depression</keyword>
  <keyword>Olanzapine</keyword>
  <keyword>add-on therapy</keyword>
  <keyword>antidepressant</keyword>
  <keyword>atypical antipsychotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

